PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients

SpringerPlus

Volumn 4, Issue 1, 2015, Pages

  Nakaoka, Kazunori ^a   Hashimoto, Senju ^a   Kawabe, Naoto ^a   Nitta, Yoshifumi ^a   Murao, Michihito ^a   Nakano, Takuji ^a   Shimazaki, Hiroaki ^a   Kan, Toshiki ^a   Takagawa, Yuka ^a   Ohki, Masashi ^a   Kurashita, Takamitsu ^a   Takamura, Tomoki ^a   Nishikawa, Toru ^a   Ichino, Naohiro ^a   Osakabe, Keisuke ^a   Yoshioka, Kentaro ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Cirrhosis; HCC; HCV; PNPLA3; SNP

Indexed keywords

EID: 84923239488     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-015-0870-5     Document Type: Article

References (43)

1. Arima Y, Kawabe N, Hashimoto S, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Kobayashi K, Ichino N, Osakabe K, Nishikawa T, Okumura A, Ishikawa T, Yoshioka K (2010) Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res 40:383–392, doi:10.1111/j.1872-034X.2009.00618.x
2. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N (2010) Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52:518–527, doi:10.1002/hep.23691
3. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22:5093–5107, doi:10.1038/sj.onc.1206557
4. Bota S, Sporea I, Sirli R, Popescu A, Jurchis A (2013) Factors which influence the accuracy of acoustic radiation force impulse (ARFI) elastography for the diagnosis of liver fibrosis in patients with chronic hepatitis C. Ultrasound Med Biol 39:407–412, doi:10.1016/j.ultrasmedbio.2012.09.017
5. Bota S, Sporea I, Sirli R, Popescu A, Danila M, Jurchis A, Gradinaru-Tascau O (2014) Factors associated with the impossibility to obtain reliable liver stiffness measurements by means of Acoustic Radiation Force Impulse (ARFI) elastography–analysis of a cohort of 1,031 subjects. Eur J Radiol 83:268–272, doi:10.1016/j.ejrad.2013.11.019
6. Burza MA, Pirazzi C, Maglio C, Sjoholm K, Mancina RM, Svensson PA, Jacobson P, Adiels M, Baroni MG, Boren J, Ginanni Corradini S, Montalcini T, Sjostrom L, Carlsson LM, Romeo S (2012) PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 44:1037–1041, doi:10.1016/j.dld.2012.05.006
7. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY (2011) Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 55:529–535, doi:10.1016/j.jhep.2010.12.020
8. Chen SH, Li YF, Lai HC, Kao JT, Peng CY, Chuang PH, Su WP, Chiang IP (2012) Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. BMC Gastroenterol 12:105, doi:10.1186/1471-230x-12-105
9. Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ (2012) The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci 57:2213–2221, doi:10.1007/s10620-012-2171-y
10. Dunn W, O'Neil M, Zhao J, Wu CH, Roberts B, Chakraborty S, Sherman C, Weaver B, Taylor R, Olson J, Olyaee M, Gilroy R, Schmitt T, Wan YY, Weinman SA (2014) Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology 59:453–460, doi:10.1002/hep.26758
11. Ezzikouri S, Alaoui R, Tazi S, Nadir S, Elmdaghri N, Pineau P, Benjelloun S (2014) The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients. Infect Genet Evol 21C:179–183, doi:10.1016/j.meegid.2013.11.005
12. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M (2013) Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 58:1918–1929, doi:10.1002/hep.26641
13. Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C (2009) Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 252:595–604, doi:10.1148/radiol.2523081928
14. Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrie N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P (2013) PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 58:312–318, doi:10.1016/j.jhep.2012.09.036
15. Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T (2014) Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. J Viral Hepat 21:357–365, doi:10.1111/jvh.12151
16. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K (1998) Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27:1394–1402, doi:10.1002/hep.510270529
17. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Japan Study Group of Nonalcoholic Fatty Liver D (2012) Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 7:e38322, doi:10.1371/journal.pone.0038322
18. Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A, Hotta K (2013) Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 132:783–792, doi:10.1007/s00439-013-1294-3
19. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, Wongsiriroj N, Nagy HM, Ivanova PT, Scott SA, Knittelfelder O, Rechberger GN, Birner-Gruenberger R, Eder S, Brown HA, Haemmerle G, Oberer M, Lass A, Kershaw EE, Zimmermann R, Zechner R (2012) Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 15:691–702, doi:10.1016/j.cmet.2012.04.008
20. Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, Hiroishi K, Kobayashi M, Kumada H, Imawari M (2012) Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 19:608–614, doi:10.1111/j.1365-2893.2011.01580.x
21. Moritou Y, Ikeda F, Iwasaki Y, Baba N, Takaguchi K, Senoh T, Nagano T, Takeuchi Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K (2013) Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C. Springerplus 2:251, doi:10.1186/2193-1801-2-251
22. Nakamura M, Kanda T, Nakamoto S, Miyamura T, Jiang X, Wu S, Yokosuka O (2013) No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV. PLoS One 8:e81312, doi:10.1371/journal.pone.0081312
23. Nischalke HD, Berger C, Luda C, Berg T, Muller T, Grunhage F, Lammert F, Coenen M, Kramer B, Korner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U (2011) The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One 6:e27087, doi:10.1371/journal.pone.0027087
24. Nishikawa T, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Mizuno Y, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Ichino N, Osakabe K, Yoshioka K (2014) Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. World J Gastroenterol 20:1289–1297, doi:10.3748/wjg.v20.i5.1289
25. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825–832
26. Rembeck K, Maglio C, Lagging M, Christensen PB, Farkkila M, Langeland N, Buhl MR, Pedersen C, Morch K, Norkrans G, Hellstrand K, Lindh M, Pirazzi C, Burza MA, Romeo S, Westin J (2012) PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet 13:82, doi:10.1186/1471-2350-13-82
27. Rizzo L, Calvaruso V, Cacopardo B, Alessi N, Attanasio M, Petta S, Fatuzzo F, Montineri A, Mazzola A, L'Abbate L, Nunnari G, Bronte F, Di Marco V, Craxi A, Camma C (2011) Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 106:2112–2120, doi:10.1038/ajg.2011.341
28. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465, doi:10.1038/ng.257
29. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52:894–903, doi:10.1002/hep.23759
30. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K (2013) Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res 44:E137–144, doi:10.1111/hepr.12258
31. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567, doi:10.1016/s1473-3099(05)70216-4
32. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53:1883–1894, doi:10.1002/hep.24283
33. Sporea I, Bota S, Peck-Radosavljevic M, Sirli R, Tanaka H, Iijima H, Badea R, Lupsor M, Fierbinteanu-Braticevici C, Petrisor A, Saito H, Ebinuma H, Friedrich-Rust M, Sarrazin C, Takahashi H, Ono N, Piscaglia F, Borghi A, D'Onofrio M, Gallotti A, Ferlitsch A, Popescu A, Danila M (2012) Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. Eur J Radiol 81:4112–4118, doi:10.1016/j.ejrad.2012.08.018
34. Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K (2013) The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 48:405–412, doi:10.1007/s00535-012-0647-3
35. Trepo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlue J, Kreipe H, Deviere J, Manns M, Trepo C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C (2011) Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54:60–69, doi:10.1002/hep.24350
36. Trepo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Deviere J, Mathurin P, Moreno C, Romeo S, Deltenre P (2014) Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 59:2170–2177, doi:10.1002/hep.26767
37. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP (2010) Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51:1209–1217, doi:10.1002/hep.23622
38. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S (2011) Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53:791–799, doi:10.1002/hep.24123
39. Valenti L, Aghemo A, Stattermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S (2012) Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 35:1434–1442, doi:10.1111/j.1365-2036.2012.05109.x
40. Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M (2014) Prediction of efficacy to pegylated interferon-alpha-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks. Hepatol Res 44:179–186, doi:10.1111/hepr.12101
41. Yoon KT, Lim SM, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Cho M, Lee JW, Kim SU (2012) Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci 57:1682–1691, doi:10.1007/s10620-012-2044-4
42. Yoshizawa H, Tanaka J, Miyakawa Y (2006) National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 49:7–17, doi:10.1159/000087257
43. Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, Sagnelli E, Perrone L, Adinolfi LE, Miraglia del Giudice E (2013) Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 20:517–523, doi:10.1111/jvh.12053